Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
Int J Mol Sci. 2023 Dec 28;25(1):436. doi: 10.3390/ijms25010436.
Somatostatin (SST), a growth hormone inhibitory peptide, is expressed in endocrine and non-endocrine tissues, immune cells and the central nervous system (CNS). Post-release from secretory or immune cells, the first most appreciated role that SST exhibits is the antiproliferative effect in target tissue that served as a potential therapeutic intervention in various tumours of different origins. The SST-mediated in vivo and/or in vitro antiproliferative effect in the tumour is considered direct via activation of five different somatostatin receptor subtypes (SSTR1-5), which are well expressed in most tumours and often more than one receptor in a single cell. Second, the indirect effect is associated with the regulation of growth factors. SSTR subtypes are crucial in tumour diagnosis and prognosis. In this review, with the recent development of new SST analogues and receptor-specific agonists with emerging functional consequences of signaling pathways are promising therapeutic avenues in tumours of different origins that are discussed.
生长抑素（SST）是一种生长激素抑制肽，在内分泌和非内分泌组织、免疫细胞和中枢神经系统（CNS）中表达。从分泌细胞或免疫细胞释放后，SST 首先表现出的最重要作用是在靶组织中的抗增殖作用，这为不同来源的各种肿瘤的潜在治疗干预提供了可能。SST 介导的体内和/或体外肿瘤抗增殖作用被认为是通过激活五种不同的生长抑素受体亚型（SSTR1-5）直接发挥作用的，这些受体亚型在大多数肿瘤中表达良好，并且在单个细胞中通常不止一种受体。其次，间接作用与生长因子的调节有关。SSTR 亚型在肿瘤的诊断和预后中至关重要。在这篇综述中，随着新的 SST 类似物和受体特异性激动剂的发展，以及信号通路的新兴功能后果，这些都是不同来源肿瘤有前途的治疗途径，对此进行了讨论。
